• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Delcath Systems Inc.

Delcath names new CEO

October 2, 2020 By Sean Whooley

delcath-systems

Delcath Systems (OTC:DCTH) announced that it appointed Gerard Michel as its new CEO, effective yesterday, Oct. 1, 2020. Michel assumed the role yesterday and also was appointed as a Class I director on the company’s board of directors, with that role continuing until the expiry of his term at the company’s 2022 annual meeting of stockholders, […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Oncology Tagged With: Delcath Systems Inc., Personnel Moves

Delcath Systems announces reverse stock split

December 24, 2019 By Chris Newmarker

delcath-systems

A reverse stock split went into effect today for Delcath Systems (OTC:DCTH) — developer of the Chemostat hepatic delivery system for treating cancer. The 1-for-700 reverse stock split is meant to reduce the number of common stock shares and shares reserved for issuance to 1.2 million, from a previous 1.4 billion. The authorized number of shares […]

Filed Under: Business/Financial News, Featured, Oncology, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath Systems raises another $9.5m

August 20, 2019 By Nancy Crotti

delcath-systems

Delcath Systems (OTC:DCTH) has closed on a $9.5 million private placement round, bringing the total amount raised since July to $29.5 million. The Queensbury, N.Y.-based company priced the round at $1,000 per unit, with each unit consisting of a preferred convertible share worth 16,667 common shares, at a 6¢ strike price, and a five-year warrant […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Oncology, Uncategorized, Wall Street Beat Tagged With: BTG, Delcath Systems Inc.

Delcath Systems closes $20m private placement

July 23, 2019 By Danielle Kirsh

delcath-systems

Delcath Systems (OTC:DCTH) last week said that it closed a $20 million private placement round for the liver cancer treatment it developed. The Queensbury, N.Y.-based company priced the round at $1,000 per unit, with each unit consisting of a preferred convertible share worth 16,667 common shares, at a 6¢ strike price, and a five-year warrant another […]

Filed Under: Oncology Tagged With: Delcath Systems Inc.

Delcath wins approval for Chemosat in Brazil

February 11, 2019 By Sarah Faulkner

Delcath Systems - updated logo

Delcath Systems (OTC:DCTH) said today that it won medical device approval for its Chemosat hepatic delivery system from the national health authority in Brazil. The New York-based company plans to market and sell Chemosat in Brazil for the percutaneous intra-arterial administration of melphalan hydrochloride to the liver with subsequent extracorporeal filtration of blood. Delcath will work with […]

Filed Under: Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath inks European licensing deal for Chemosat

December 26, 2018 By Sarah Faulkner

Delcath Systems - updated logo

Delcath Systems (OTC:DCTH) said this week that it inked a licensing deal with Germany-based medac for the commercialization of Chemosat in Europe. According to the terms of the seven-year agreement, Delcath’s European subsidiary will exclusively license its Chemosat system to Medac for sale in the EU, Norway, Liechtenstein, Switzerland and the UK. Medac is slated […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath registers $100m offering

October 26, 2018 By Sarah Faulkner

Delcath Systems - updated logo

Delcath Systems (NSDQ:DCTH) registered a $100 million offering with the SEC this week to support the development of its system designed to administer high-dose chemotherapy to the liver. The company’s product, melphalan hydrochloride for injection for use with the Delcath hepatic delivery system, won CE Mark clearance in Europe in 2012 and is under consideration by […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Delcath Systems Inc.

DelCath closes $8m rights offering

September 28, 2018 By Fink Densford

Delcath Systems

Delcath Systems (NSDQ:DCTH) said yesterday it closed a previously announced rights offering bringing in approximately $8.1 million. The New York-based company said that it received approximately 4.3 million basic subscriptions and 418,207 oversubscriptions for a total of approximately 4.7 million subscriptions. Each subscription equates to a single share of Delcath’s common stock, the company said, with […]

Filed Under: Business/Financial News, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath registers $10m offering

April 10, 2018 By Sarah Faulkner

Delcath Systems

Delcath Systems (NSDQ:DCTH) proposed offering up to $5 million in units and $5 million in pre-funded units this week to fund the company’s clinical and commercial operations. The New York-based company plans to offer 500,000,000 units made up of Series C units with one share of common stock and Series E warrants to buy one share […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Delcath Systems Inc.

Delcath approves massive reverse split

April 9, 2018 By Sarah Faulkner

Delcath Systems

Delcath Systems (NSDQ:DCTH) said today that shareholders approved a bid to increase the company’s authorized shares of common stock from 500,000,000 to 1,000,000,000. The New York-based oncology group also voted to effect a reverse stock split of Delcath’s common stock at a range of 1-for-100 to 1-for-500. The board of directors have until April 6, 2019 […]

Filed Under: Drug-Device Combinations, Featured, Oncology, Wall Street Beat Tagged With: Delcath Systems Inc.

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS